Cizzle Biotechnology Expanding into the USA and Transforming Cancer Screening
In a recent interview with DirectorsTalk, Dr. Allan Syms, Executive Chairman of Cizzle Biotechnology, shared exciting updates about the company's expansion into the USA and its transformative impact on early-stage lung cancer detection through its CIZ1B biomarker blood test.
Key Takeaways from the Interview:
1. Expanding into the U.S. Market
Dr. Syms discussed Cizzle Biotechnology’s strategic growth in North America through Cizzle Bio, Inc. (BIO), the company’s U.S.-based entity. BIO has secured key partnerships to introduce the CIZ1B biomarker test for early detection of lung cancer, addressing the needs of one of the world's largest healthcare markets.
2. Why Early Detection Matters
Lung cancer is the leading cause of cancer deaths worldwide, often due to late diagnosis. Dr. Syms emphasized the importance of early detection, explaining how BIO’s CIZ1B biomarker test offers a non-invasive, highly sensitive, and cost-effective solution for detecting lung cancer at its earliest stages. With a 95% sensitivity rate, this test could dramatically improve survival rates and reduce the financial burden on healthcare systems.
3. U.S. Partnerships and Clinical Collaborations
In the interview, Dr. Syms highlighted BIO’s partnerships with leading U.S. institutions, including a collaboration with the Moffitt Cancer Center in Florida. These partnerships will allow BIO to clinically evaluate the biomarker in real-world settings, crucial for FDA approvals and CLIA accreditation, which are expected by the end of 2024.
4. Scaling and Market Launch in 2025
Dr. Syms confirmed that Cizzle Bio is on track to launch the CIZ1B biomarker test in the U.S. by April 2025, supported by approved reimbursement codes that will make the test widely accessible to patients. Cizzle Bio, Inc. will oversee the clinical evaluations and commercialization of the test across North America, driving the company’s strategic expansion.
5. Looking Ahead
Beyond lung cancer, Cizzle Biotechnology and BIO are actively exploring the broader applications of their CIZ1B biomarker technology for other forms of cancer. The company remains committed to global partnerships and innovation, aiming to expand into new regions and further improve cancer diagnostics.
